View from Brussels

Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

Articles

Though members of the industry have made reassuring comments about progress with candidate COVID vaccines, they acknowledge it could be next year, at best, before any real response would be available. 

Europe's COVID Vaccine Bids Still Veiled in Secrecy

EMA has launched a "communication perception survey" looking for honest views from among the widest audience on how well it is doing. 

EMA Looks to Its Image

Teenagers with cancer could benefit from a proposed initiative to lower the age barrier for participation in trials for new oncology drugs.

EU Specialists: Ease the Age Barrier for Cancer Clinical Trials

Social media uses transparency to highlight alleged gaps in clinical trial transparency and offers a more powerful approach to health campaigners.



Trial Non-Reporting a European as Well as U.S. Problem

Peter O’Donnell explores where the EU stands today in R&D pursuits for new antibacterial therapies.    

How to Boost Research for New Antibiotics—And How Not To

The regulatory path for virtual studies is nebulous and potentially difficult to navigate-finding a way forward requires a thorough understanding of the terrain and how to apply existing legal frameworks.

Virtual Clinical Studies: Finding a Path to Execution

Higher screen failure and patient dropout rates are raising the imperative to pilot and implement new study conduct models in trial recruitment and retention.

Can Recruitment and Retention Get Any Worse?

ClinOne Teams Up with Boston Children’s Hospital

A shift in emphasis in healthcare strategy could reduce attention and funding to therapy and impose tougher controls over research projects, or possible mean a boost for innovative healthcare. A look at where these trends may go.



Who’s Going to Be Disrupted by Shifts in European Health Strategy?

The two-year inquiry into possible maladministration at the EMA has intensified.

